AVNS vs. LIVN, WRBY, ENOV, TNDM, TMDX, CNMD, LMAT, SLNO, INMD, and CDRE
Should you be buying Avanos Medical stock or one of its competitors? The main competitors of Avanos Medical include LivaNova (LIVN), Warby Parker (WRBY), Enovis (ENOV), Tandem Diabetes Care (TNDM), TransMedics Group (TMDX), CONMED (CNMD), LeMaitre Vascular (LMAT), Soleno Therapeutics (SLNO), InMode (INMD), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.
Avanos Medical vs.
LivaNova (NASDAQ:LIVN) and Avanos Medical (NYSE:AVNS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking.
LivaNova received 309 more outperform votes than Avanos Medical when rated by MarketBeat users. Likewise, 69.42% of users gave LivaNova an outperform vote while only 55.84% of users gave Avanos Medical an outperform vote.
In the previous week, Avanos Medical had 2 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for Avanos Medical and 4 mentions for LivaNova. LivaNova's average media sentiment score of 1.21 beat Avanos Medical's score of 0.10 indicating that LivaNova is being referred to more favorably in the media.
97.6% of LivaNova shares are owned by institutional investors. Comparatively, 95.2% of Avanos Medical shares are owned by institutional investors. 0.3% of LivaNova shares are owned by company insiders. Comparatively, 3.9% of Avanos Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
LivaNova has higher revenue and earnings than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.
LivaNova has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
LivaNova presently has a consensus price target of $69.17, indicating a potential upside of 43.20%. Given LivaNova's stronger consensus rating and higher possible upside, analysts plainly believe LivaNova is more favorable than Avanos Medical.
Avanos Medical has a net margin of 2.30% compared to LivaNova's net margin of 1.91%. LivaNova's return on equity of 13.81% beat Avanos Medical's return on equity.
Summary
LivaNova beats Avanos Medical on 16 of the 19 factors compared between the two stocks.
Get Avanos Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avanos Medical Competitors List
Related Companies and Tools
This page (NYSE:AVNS) was last updated on 1/18/2025 by MarketBeat.com Staff
